BPD Research
Long/short equity

Array BioPharma: An Exciting Year Ahead

2013 will be an exciting year for Array BioPharma Inc. (NASDAQ:ARRY) as it transitions into a late-stage development company. It has a diverse pipeline of drugs with up to six potential Phase III decisions over the next year. ARRY also enjoys potentially lucrative partnerships with several large pharmaceutical companies, including Amgen (NASDAQ:AMGN), Astra Zeneca (NYSE:AZN), Celgene (NASDAQ:CELG), Genentech, and Novartis (NYSE:NVS). The potential for significant milestone and royalty revenue from these partnerships is offset by the length of time before any of the drugs may reach commercialization and the inherent risks of drug development.

Pipeline Overview

(click to enlarge)

Source: March 2013 Investor Presentation

ARRY currently has four drugs in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details